Equities

Psychemedics Corp

PMD:NAQ

Psychemedics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.33
  • Today's Change-0.01 / -0.43%
  • Shares traded15.09k
  • 1 Year change+12.02%
  • Beta0.6803
Data delayed at least 15 minutes, as of Nov 22 2024 18:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.

  • Revenue in USD (TTM)20.26m
  • Net income in USD-3.00m
  • Incorporated1986
  • Employees116.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inspire Veterinary Partners Inc17.13m-19.33m7.10m156.00------0.4146-134.72-134.724.54-0.6310.816521.61246.52109,778.20-89.79---190.96--19.47---109.98--0.1311-2.741.20--69.56---206.68------
Ontrak Inc11.24m-35.68m7.72m102.00--0.5432--0.6868-10.55-10.553.023.370.5207--21.66110,186.30-123.82-54.80-228.86-73.3764.0053.50-237.77-71.95---2.270.4088---12.20-3.4439.08--99.58--
Univec Inc-100.00bn-100.00bn7.95m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Healthlynked Corp3.32m-6.19m9.14m38.00------2.75-0.0222-0.02220.0119-0.00690.786215.8281.3287,385.27-146.48-119.37-966.37-332.2247.3355.81-186.32-119.260.4586-4.69-----2.3220.4357.08---12.94--
Xcelerate Inc3.96m-296.19k9.90m1.00--7.12--2.50-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Pacific Health Care Organization Inc6.17m869.09k10.50m30.0012.090.921411.591.700.06780.06780.48120.890.5259--6.40205,557.707.417.297.937.8179.0382.7514.0913.28----0.00---2.00-3.7055.80-10.80-15.93--
Oncology Institute Inc378.93m-57.46m11.70m800.00--0.7565--0.0309-0.7706-0.77065.080.20491.9129.197.36473,666.30-35.34---44.12--14.1819.54-18.53-9.992.27-7.440.8553--28.4223.43-99,919.12--45.68--
Interpace Biosciences Inc44.89m4.89m11.80m108.002.43--2.290.2631.101.0610.13-2.533.1715.357.41415,675.9034.54-38.19---69.7360.4649.4410.88-41.010.52698.11----26.3112.93118.96--0.9184--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)100.41m-6.69m11.96m1.29k--3.116.040.1191-0.1485-0.14852.210.08061.2920.8277.3678,081.45-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Streamline Health Solutions Inc20.30m-18.82m12.75m77.00--12.03--0.628-0.3277-0.32770.34990.25110.4397--7.64263,636.40-40.77-22.06-56.63-31.6950.8649.96-92.72-54.55---4.460.4395---9.210.2057-64.31---11.72--
Psychemedics Corp.20.26m-3.00m13.79m116.00--2.53--0.6809-0.5142-0.51423.470.92381.69--5.12174,637.90-25.02-7.44-40.58-9.7038.3637.55-14.78-6.26---292.900.0969---12.45-12.33-283.21---33.32--
PharmChem Inc6.00m1.27m14.64m170.0011.554.7311.532.440.27270.27271.290.66611.677.238.04--35.37--44.59--64.09--21.17--4.45--0.00--3.50---16.95------
ProPhase Labs Inc12.75m-27.76m18.55m113.00--0.3888--1.45-1.50-1.500.68872.000.1393.740.3629112,858.40-30.250.9106-40.111.12-32.3850.32-217.640.93251.33-12.780.2837665.78-63.8127.59-190.90--86.46--
Concord Medical Services Hldgs Ltd (ADR)65.18m-52.36m19.32m727.00------0.2964-11.99-11.9914.92-68.070.074313.395.3589,656.95-10.23-9.49-111.95-39.24-17.13-15.06-137.67-134.560.4556-1.890.6369--13.8423.0039.21---6.88--
Data as of Nov 22 2024. Currency figures normalised to Psychemedics Corp's reporting currency: US Dollar USD

Institutional shareholders

20.12%Per cent of shares held by top holders
HolderShares% Held
22NW LPas of 30 Sep 2024276.03k4.68%
Renaissance Technologies LLCas of 30 Sep 2024270.86k4.60%
The Vanguard Group, Inc.as of 30 Sep 2024251.28k4.26%
RBF Capital LLCas of 30 Sep 2024142.14k2.41%
BlackRock Fund Advisorsas of 30 Sep 202466.41k1.13%
Wedbush Securities, Inc. (Investment Management)as of 30 Sep 202447.87k0.81%
G1 Execution Services LLCas of 30 Sep 202447.39k0.80%
Geode Capital Management LLCas of 30 Sep 202442.68k0.72%
Citadel Securities LLCas of 30 Sep 202421.51k0.37%
SMP Asset Management LLCas of 30 Sep 202420.00k0.34%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.